DL-Isovaleryl-prolin | 60804-39-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: DL-Isovaleryl-prolin
• 英文别名: N-iso-valeryl-L-proline；1-(3-Methylbutanoyl)pyrrolidine-2-carboxylic acid
• CAS: 60804-39-9
• 化学式: C₁₀H₁₇NO₃
• mdl: MFCD08442897
• 分子量: 199.25
• InChiKey: VBVLZADPBRUAGF-UHFFFAOYSA-N

物化性质

• 沸点：
  379.6±35.0 °C(Predicted)
• 密度：
  1.150±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为产物：
  描述：

  异戊酰氯 、 L-脯氨酸 在 magnesium sulfate 作用下， 以 aq. NaOH 为溶剂， 生成 DL-Isovaleryl-prolin
  参考文献：
  名称：

  Biologically active n-acylprolydipeptides having antiamnestic,

  摘要：

  描述了一种具有精神活性且特别有助于学习和记忆的N-酰基脯氨酰二肽类新物质。发明的N-酰基脯氨酰二肽具有以下公式：##STR1## 其中R1=（C4-C5）烷基，环烷基，芳烷基或芳基；R2=H1（C1-C4）烷基，碳酰胺烷基或碳酸烷氧基烷基；R3=NH2，NH（烷基），N（烷基）2，OH或烷氧基；n=0-3，最好是0-2。

  公开号：

  US05439930A1

文献信息

• Substituted Morphinans and the Use Thereof
  申请人：Purdue Pharma L.P.

  公开号：US20140187573A1

  公开（公告）日：2014-07-03

  The application is directed to compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2 , R 3 , R 4a , and R 4b are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.

  本申请涉及式I化合物： 及其医药可接受的盐和溶剂化物，其中R1、R2、R3、R4a和R4b的定义如说明书中所述。本发明还涉及使用式I化合物来治疗对一或多个阿片受体调节有反应的疾病，或作为合成中间体。本发明中的某些化合物特别适用于治疗疼痛。
• PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE
  申请人：Heffernan Michele L. R.

  公开号：US20110034434A1

  公开（公告）日：2011-02-10

  The invention relates to prodrugs of fused heterocyclic inhibitors of D-amino oxidase (DAAO) and methods of treating diseases and conditions, wherein modulation of D-amino acid oxidase activity, D-serine levels, D-serine oxidative products and NMDA receptor activity in the nervous system of a mammalian subject is effective.

  该发明涉及融合杂环抑制剂的前药，用于治疗疾病和病况的方法，其中在哺乳动物主体的神经系统中调节D-氨基酸氧化酶活性、D-丝氨酸水平、D-丝氨酸氧化产物和NMDA受体活性是有效的。
• Nitrile derivatives that inhibit cathepsin K
  申请人：——

  公开号：US20010008901A1

  公开（公告）日：2001-07-19

  Compounds of the formula: 1 wherein R 1 to R 7 and Y are as defined in the specification, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof, are useful for treating diseases associated with cystein proteases, such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis, atherosclerosis, myocardial infarction, angina pectoris, instable angina pectoris, stroke, plaque rupture, transient ischemic attacks, amaurosis fugax, peripheral arterial occlusive disease, restenosis after angioplasty and stent placement, abdominal aortic aneurysm formation, inflammation, autoimmune disease, malaria, ocular fundus tissue cytopathy and respiratory disease.

  该公式化合物：其中R1到R7和Y如规范中定义，并且其药用盐和/或药用酯是用于治疗与半胱氨酸蛋白酶相关的疾病，如骨质疏松症、骨关节炎、类风湿性关节炎、肿瘤转移、肾小球肾炎、动脉粥样硬化、心肌梗死、心绞痛、不稳定性心绞痛、中风、斑块破裂、短暂性缺血性发作、瞬间性视网膜动脉阻塞、外周动脉闭塞性疾病、血管成形术和支架植入术后再狭窄、腹主动脉瘤形成、炎症、自身免疫疾病、疟疾、眼底组织细胞病变和呼吸道疾病的有用化合物。
• Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
  申请人：COCRYSTAL PHARMA, INC.

  公开号：US11014941B2

  公开（公告）日：2021-05-25

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient a safe and effective amount of a compound represented by any of Formulas I-III, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a safe and effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制生物样本或患者体内流感病毒复制、减少生物样本或患者体内流感病毒数量以及治疗患者流感的方法，包括向所述生物样本或患者施用安全有效量的由式I-III中任一项代表的化合物或其药学上可接受的盐。药物组合物包括安全有效量的此类化合物或其药学上可接受的盐，以及药学上可接受的载体、佐剂或载体。
• NITRILE DERIVATIVES AS CATHEPSIN K INHIBITORS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1244621B1

  公开（公告）日：2006-09-13